{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:30Z","timestamp":1792791930726,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome Trust"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.blre.2020.100708","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T21:39:15Z","timestamp":1589837955000},"page":"100708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice"],"prefix":"10.1016","volume":"42","author":[{"given":"Joe","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Nangalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100708_bb0005","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2020.100708_bb0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in Polycythemia Vera and Idiopathic Erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0030","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0035","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.blre.2020.100708_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0045","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of Calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0050","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0055","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0065","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British Committee for Standards in haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0080","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.12985","article-title":"Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in haematology guidelines for investigation and Management of Myelofibrosis 2012","volume":"167","author":"Reilly","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0085","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients","author":"Cabagnols","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0095","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0110","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.blre.2020.100708_bb0120","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0125","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0130","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0135","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant Calreticulin requires both its mutant C-terminus and the Thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2020.100708_bb0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0145","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0150","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl W515L\/K mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","article-title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions","volume":"130","author":"Buscarlet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0170","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0180","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal Hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0185","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0190","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100708_bb0195","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2020.100708_bb0200","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0205","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid Leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0215","doi-asserted-by":"crossref","first-page":"a030320","DOI":"10.1101\/cshperspect.a030320","article-title":"DNMT3A in Leukemia","volume":"7","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2020.100708_bb0220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","article-title":"DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications","volume":"119","author":"Hou","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0225","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2020.100708_bb0230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2020.100708_bb0245","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1673.1673","article-title":"Prognostic impact of ASXL1 mutations in MDS and CMML","volume":"126","author":"Sallman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0255","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100708_bb0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-013-2093-2","article-title":"EZH2, an epigenetic driver of prostate cancer","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0265","first-page":"422","article-title":"EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2\/\u22129 pathway","volume":"8","author":"Chien","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.blre.2020.100708_bb0270","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100708_bb0275","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0280","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0285","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0290","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0295","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0300","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0305","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2013-01-480970","article-title":"Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms","volume":"122","author":"Przychodzen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0310","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0315","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100708_bb0320","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0325","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv347","article-title":"PPM1D mosaic truncating variants in ovarian Cancer cases may be treatment-related somatic mutations","volume":"108","author":"Pharoah","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2020.100708_bb0330","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11725","article-title":"Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer","volume":"493","author":"Ruark","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0340","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0345","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","article-title":"Specific JAK2 mutation (JAK2R683) and multiple gene deletions in down syndrome acute lymphoblastic leukemia","volume":"113","author":"Kearney","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0350","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2020.100708_bb0355","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjh.12283","article-title":"Diagnostic pathway for the investigation of thrombocytosis","volume":"161","author":"Harrison","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0360","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.20011170","article-title":"Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk","volume":"195","author":"Takaki","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0365","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20110540","article-title":"A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2","volume":"209","author":"Kaufmann","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0370","series-title":"Mod. Trends Hum. Leuk. III","first-page":"53","article-title":"Use of Glucose-6-Phosphate Dehydrogenase Markers to Study Human Myeloproliferative Disorders","author":"Fialkow","year":"1979"},{"key":"10.1016\/j.blre.2020.100708_bb0375","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.183.2.561","article-title":"Clonal stability of blood cell lineages indicated by X-chromosomal transcriptional polymorphism","volume":"183","author":"Prchal","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0380","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0385","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2020.100708_bb0390","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0395","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/leu.2017.1","article-title":"Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm","volume":"31","author":"Yao","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0400","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0405","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0410","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0415","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 Signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0420","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0425","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0430","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2020.100708_bb0440","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2020.100708_bb0445","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0450","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100708_bb0455","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0460","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0465","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0470","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0475","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0480","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0485","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0490","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100708_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","article-title":"Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo","volume":"23","author":"Jeong","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2020.100708_bb0500","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0505","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41375-018-0159-0","article-title":"ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF","volume":"33","author":"Triviai","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0510","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0515","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0520","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0525","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100708_bb0530","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2020.100708_bb0535","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100708_bb0540","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0545","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0550","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0555","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0560","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0565","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0570","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0575","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0580","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/leu.2014.48","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms","volume":"28","author":"Oddsson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0585","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2020.100708_bb0590","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0595","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ng.467","article-title":"A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium","volume":"41","author":"Soranzo","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0600","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ng.466","article-title":"Multiple loci influence erythrocyte phenotypes in the CHARGE consortium","volume":"41","author":"Ganesh","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002113","article-title":"Multiple loci are associated with white blood cell phenotypes","volume":"7","author":"Nalls","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0610","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/hmg\/dds534","article-title":"GWAS of blood cell traits identifies novel associated loci and epistatic interactions in Caucasian and African-American children","volume":"22","author":"Li","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0615","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.462","article-title":"Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels","volume":"41","author":"Chambers","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0620","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ng.456","article-title":"Common variants in TMPRSS6 are associated with iron status and erythrocyte volume","volume":"41","author":"Benyamin","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100708_bb0625","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years","volume":"123","author":"Gruppo Italiano Studio Policitemia* GIS","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2020.100708_bb0630","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0635","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/leu.2017.233","article-title":"The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms","volume":"32","author":"Zhan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100708_bb0640","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in Polycythemia Vera, chronic Myelocytic Leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2020.100708_bb0645","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V94.11.3717","article-title":"Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia","volume":"94","author":"Aguayo","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0650","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF03033732","article-title":"Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD)","volume":"9","author":"Wr\u00f3bel","year":"2003","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.blre.2020.100708_bb0655","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood-2018-99-113495","article-title":"Niche heterogeneity impacts evolution of myeloproliferative neoplasms driven by the same oncogenic pathway","volume":"132","author":"Korn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0660","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0665","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0670","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0675","first-page":"402","article-title":"A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation","volume":"88","author":"Vannucchi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0680","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.20110752","article-title":"Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors","volume":"208","author":"Pronk","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100708_bb0685","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100708_bb0690","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.13198","article-title":"Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study group","volume":"102","author":"Birgegard","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0695","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2020.100708_bb0700","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100708_bb0705","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0710","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2016.06.009","article-title":"Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms","volume":"48","author":"Angona","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100708_bb0715","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0720","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature25455","article-title":"Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells","volume":"554","author":"Carrelha","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0725","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","article-title":"Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy","volume":"502","author":"Sanjuan-Pla","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0730","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/ncomms11075","article-title":"Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells","volume":"7","author":"Grover","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2020.100708_bb0735","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jbior.2018.11.007","article-title":"Heterogeneity in myeloproliferative neoplasms: causes and consequences","volume":"71","author":"O\u2019Sullivan","year":"2019","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.blre.2020.100708_bb0740","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2016-01-636381","article-title":"Clonal hematopoiesis in acquired aplastic anemia","volume":"128","author":"Ogawa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0745","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1474-9726.2011.00675.x","article-title":"Age-related changes in human hematopoietic stem\/progenitor cells","volume":"10","author":"Kuranda","year":"2011","journal-title":"Aging Cell"},{"key":"10.1016\/j.blre.2020.100708_bb0750","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.seminhematol.2016.10.004","article-title":"Age-associated changes in human hematopoietic stem cells","volume":"54","author":"Pang","year":"2017","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2020.100708_bb0755","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1182\/blood-2018-99-116015","article-title":"Aging of bone marrow microenvironment promotes myeloid Bias of hematopoietic progenitors and is a target in age-related myeloproliferative neoplasms","volume":"132","author":"Ho","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0760","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/bloodadvances.2017007047","article-title":"JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics","volume":"1","author":"McKerrell","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100708_bb0765","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.leukres.2011.09.029","article-title":"Influence of JAK2 46\/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms","volume":"36","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100708_bb0770","unstructured":"Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition."},{"key":"10.1016\/j.blre.2020.100708_bb0775","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0780","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2020.100708_bb0785","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0790","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"Sekhar","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0795","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100708_bb0800","first-page":"8","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100708_bb0805","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100708_bb0810","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0815","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic Score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100708_bb0820","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V124.21.406.406","article-title":"Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100708_bb0825","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100708_bb0830","article-title":"The 100 000 genomes project: bringing whole genome sequencing to the NHS","volume":"361","author":"Turnbull","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2020.100708_bb0835","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMra1910138","article-title":"Genome sequencing during a Patient\u2019s journey through Cancer","volume":"381","author":"Nangalia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0840","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100708_bb0845","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:07Z","timestamp":1759436707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":169,"alternative-id":["S0268960X20300588"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100708","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100708"}}